Home › Acute Myeloid Leukemia › New York
Acute Myeloid Leukemia clinical trials in New York
71 studies for Acute Myeloid Leukemia are looking for participants at sites in New York.
Cities in New York
- New York City51 studies
- Queens21 studies
- Buffalo19 studies
- Greenburgh18 studies
- Rochester16 studies
- The Bronx15 studies
- Staten Island14 studies
- New Rochelle13 studies
- Syracuse5 studies
- Albany3 studies
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Montefiore Medical Center - Moses Campus /ID# 279399, The Bronx
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07581002Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 2, 2026 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Mount Sinai Hospital, New York
- and 5 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Roswell Park Comprehensive Cancer Center, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
- New York Presbyterian - Weill Cornell, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Northwell Health/Center for Advanced Medicine, Lake Success
- and 9 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06871410A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Up to age 21 · All sexes · Updated Sep 23, 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Northwell Health/Center for Advanced Medicine, Lake Success
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649A Study of CRD3874-SI in People With Leukemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07661095Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 9 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 18, 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- and 11 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Montefiore Medical Center, New York
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Weill Cornell, New York
- Clinical Research Allicance, Westbury
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168A Telehealth Advance Care Planning Intervention
- University of Rochester, Rochester
Recruiting
Ages 60 and older · All sexes · Updated Sep 11, 2026 · NCT05875805Cord Blood Transplant in Adults With Blood Cancers
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 21 to 65 · All sexes · Updated Sep 11, 2026 · NCT05884333A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06969430A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- New York Medical College /ID# 275597, Valhalla
RecruitingPhase 1
6 Months – 17 Years · All sexes · Updated Sep 9, 2026 · NCT07306832Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Albany Medical Center, Albany
- Montefiore Medical Center - Moses Campus, The Bronx
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Memorial Sloan Kettering Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06533761The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- and 7 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center - New York, New York
- Cohen Children's Medical Center, Queens
RecruitingPhase 3
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- State University of New York at Buffalo, Buffalo
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
- Stony Brook Cancer Center, Stony Brook
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06297551Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Roswell Park Comprehensive Cancer Center, Buffalo
- Northwell Health, LLC PRIME, Lake Success
- Memorial Sloan Kettering Cancer Center, New York
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06656494Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- New York Presbyterian Hospital-Columbia University Medical Center, New York
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07486713Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Memorial Sloan- Kettering Cancer Center, New York
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Aug 3, 2026 · NCT06177067Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, New York
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Jul 20, 2026 · NCT07155226Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Rochester Medical Center (URMC), Rochester
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 17, 2026 · NCT05429632A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Jul 17, 2026 · NCT07392242Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05442216Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Roswell Park Cancer Institute, Buffalo
- North Shore University Hospital, Lake Sucess
- Cohen Children's Medical Center of New York, New Hyde
- and 9 more
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- University of Rochester Medical Center, Rochester
Recruiting
Ages 60 and older · All sexes · Updated Jul 6, 2026 · NCT06697600A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
- Memorial Sloan Kettering Suffolk-Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05756777From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.